Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Illmer

Showing results (21-30 of 74) with videos related to

Pageof 8
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2007
Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipientChristoph Pöhlmann, Johannes Schetelig, Ulrike Reuner, et al.
Plos One|November 6, 2009
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapyMona Meyer, Daniela Rübsamen, Robert Slany, et al.
Transplantation|March 30, 2006
Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantationSusanne Auffermann-Gretzinger, Lars Eger, Martin Bornhäuser, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2003
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity studyFrank Kroschinsky, Eberhard Schleyer, Ulf Renner, et al.
Haematologica|August 6, 2002
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 yearsMarkus Schaich, Thomas Illmer, Walter Aulitzky, et al.
Biochemical and Biophysical Research Communications|November 9, 2004
ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expressionAlexander Schmeisser, Oliver Soehnlein, Thomas Illmer, et al.
Cancer Research|September 5, 2002
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patientsThomas Illmer, Ulrich S Schuler, Christian Thiede, et al.
Blood|May 31, 2002
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisChristian Thiede, Christine Steudel, Brigitte Mohr, et al.
Plos One|April 23, 2015
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for DifferentiationCornelia Brendel, Sabine Teichler, Axel Millahn, et al.
Atherosclerosis|December 9, 2004
The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instabilityAlexander Schmeisser, Rainer Marquetant, Thomas Illmer, et al.
Pageof 8

Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 2007
Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neutropenic stem cell transplant recipientChristoph Pöhlmann, Johannes Schetelig, Ulrike Reuner, et al.
Plos One|November 6, 2009
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapyMona Meyer, Daniela Rübsamen, Robert Slany, et al.
Transplantation|March 30, 2006
Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantationSusanne Auffermann-Gretzinger, Lars Eger, Martin Bornhäuser, et al.
Cancer Chemotherapy and Pharmacology|September 5, 2003
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity studyFrank Kroschinsky, Eberhard Schleyer, Ulf Renner, et al.
Haematologica|August 6, 2002
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 yearsMarkus Schaich, Thomas Illmer, Walter Aulitzky, et al.
Biochemical and Biophysical Research Communications|November 9, 2004
ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expressionAlexander Schmeisser, Oliver Soehnlein, Thomas Illmer, et al.
Cancer Research|September 5, 2002
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patientsThomas Illmer, Ulrich S Schuler, Christian Thiede, et al.
Blood|May 31, 2002
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisChristian Thiede, Christine Steudel, Brigitte Mohr, et al.
Plos One|April 23, 2015
Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for DifferentiationCornelia Brendel, Sabine Teichler, Axel Millahn, et al.
Atherosclerosis|December 9, 2004
The expression of macrophage migration inhibitory factor 1alpha (MIF 1alpha) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instabilityAlexander Schmeisser, Rainer Marquetant, Thomas Illmer, et al.
Pageof 8